High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
about
t-tests, non-parametric tests, and large studies--a paradox of statistical practice?The prognostic impact of high on-treatment platelet reactivity with aspirin or ADP receptor antagonists: systematic review and meta-analysisHigh residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistanceDyspnoea management in acute coronary syndrome patients treated with ticagrelorPerioperative management of patient with intracoronary stent presenting for noncardiac surgeryWe are 'shocked', 'frozen', and 'freed' by new data.Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin.Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgeryIndividualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials.Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group.Interplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention.Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers.The impact of smoking on clinical efficacy and pharmacodynamic effects of clopidogrel: a systematic review and meta-analysis.Greater collagen-induced platelet aggregation following cyclooxygenase 1 inhibition predicts incident acute coronary syndromes.Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study.Inflammatory and antioxidant pattern unbalance in "clopidogrel-resistant" patients during acute coronary syndromeBleeding tendency in dual antiplatelet therapy with aspirin/clopidogrel: rescue of the template bleeding time in a single-center prospective study.Warfarin doses for anticoagulation therapy in elderly patients with chronic atrial fibrillation.Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial.A pharmacodynamic study of the optimal P2Y12 inhibitor regimen for East Asian patients with acute coronary syndrome.Platelet aggregation and risk of stent thrombosis or bleeding in interventionally treated diabetic patients with acute coronary syndrome.Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study.Adenosine A2A receptor agonists with potent antiplatelet activity.Comparing of light transmittance aggregometry and modified thrombelastograph in predicting clinical outcomes in Chinese patients undergoing coronary stenting with clopidogrel.Relationship between ADP-induced platelet-fibrin clot strength and anti-platelet responsiveness in ticagrelor treated ACS patientsAdvances in our understanding of "resistance" to antiplatelet agents for prevention of ischemic strokeComparison of platelet activity measurements by use of arterial and venous blood sampling.Bleeding events and maintenance dose of prasugrel: BLESS pilot study.Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention.Isn't it about time we learned how to use blood transfusion in patients with ischemic heart disease?Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution?Inconsistencies surrounding the risk of adverse outcomes with concomitant use of clopidogrel and proton pump inhibitors.Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications.Stent thrombosis: an overview.Late stent thrombosis: the last remaining obstacle in coronary interventional therapy.Advances in the monitoring of anti-P2Y12 therapy.Personalizing antiplatelet therapy with clopidogrel.Genetic polymorphisms and drug interactions leading to clopidogrel resistance: why the Asian population requires special attention.Antiplatelets in acute coronary syndrome: personal perspectives.Platelet function testing in patients with acute coronary syndrome.
P2860
Q21261934-A18E1785-71B2-447D-A223-0732854C9AE6Q26824694-C9EA5B93-B3BB-46FB-8861-CB69F3E21005Q26824850-54614277-B679-4F8E-A44A-E44152E7FD4AQ27006816-DB0810E6-9A8F-41F1-8780-EF79D51D2489Q28075834-C5E9B4FB-3817-4B3B-AEBE-E66EAB6D51E6Q30586019-DD5F0B86-B4C4-4D82-AC84-7C7B6A7EABEDQ33637840-53D7CDEF-0190-49FD-A2E4-EBED4EB852CFQ33755419-207A1D3A-049F-4CCC-BA46-276334071612Q33804996-A1F15214-1BC4-4B99-BEDA-F09E14E3C43FQ33863833-842408E1-DB3C-4F13-B7D9-659A24170919Q33933475-93736354-9E71-4F5E-9399-A034BE15F409Q33963651-BA001484-BCE4-411F-88F8-890A4431587BQ34763870-13DFC319-218C-4C2F-B508-75B7941DE446Q35009741-8602BA9D-9D23-4B3A-BFBD-1E76E0C233C6Q35204942-E3B11367-93E2-421C-95AA-1F5DDEADC13DQ35250401-05B55654-A259-457E-8A55-EA75C791A766Q35707491-2266546A-1D97-4634-8EE6-D5E74C893EAAQ36017218-886392F1-E1B3-46F1-A08B-B1DC72E7C72BQ36039469-49E5AD71-BABF-4F30-BA7A-1C17362A0B62Q36081188-25E48C30-CF52-41E6-B899-B3DC3DCE0746Q36216424-F1300EDC-0594-4CEE-97F8-332ED515D2D1Q36244001-67667746-B0DD-4E94-99ED-B29ABE3AF53FQ36371663-9801A5FE-BE86-4A24-A349-DBD874783962Q36804776-D0DD2ADB-3BA9-4325-8A6A-06C52C7017BDQ37039218-A686A271-C1E1-40E8-AD6B-9C1FD0E547A7Q37051838-CACE0287-A608-4002-8C46-69AE91FF441EQ37252227-E0B7DB59-1F9C-4EB8-9652-C1C2B3CAD264Q37390051-934E74D7-901E-4B56-A673-3F980ABAB4B5Q37497555-B5B16A5D-9CA8-4704-83A3-3CABD3A3435AQ37686588-340EC57F-D7F9-4A47-B5F1-5A80750CDAB1Q37973457-D6F85D53-BDD6-43E3-8EEA-0A06D646676FQ37979853-B4C22A63-2244-4347-811B-EBB8E05C2BC5Q38008466-1B9BA9EB-D7B8-40E9-AD9F-9B6F5E2B413DQ38014978-57789AD2-DF36-4B89-BFEC-8D756281DD32Q38023285-930E701A-0712-4D2D-914E-0F55997B5DF9Q38037121-64FD92C2-26AC-4741-A5AF-76D103A9348CQ38040698-C1C5E4AF-E455-47F1-8588-605E03F94E08Q38056525-7BFDEC00-B1BB-408D-BBCE-EC24B279A3F8Q38068595-C271CE5E-E02F-49A8-BFCA-4A0B40E5E7BCQ38080466-7BAA3B9E-0DD6-4EB4-AC7D-3EAF382BC1CF
P2860
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
High residual platelet reactiv ...... nary syndromes undergoing PCI.
@en
type
label
High residual platelet reactiv ...... nary syndromes undergoing PCI.
@en
prefLabel
High residual platelet reactiv ...... nary syndromes undergoing PCI.
@en
P2093
P50
P356
P1476
High residual platelet reactiv ...... onary syndromes undergoing PCI
@en
P2093
Angela Migliorini
David Antoniucci
Gian Franco Gensini
Guido Parodi
Piergiovanni Buonamici
Renato Valenti
Rosanna Abbate
P304
P356
10.1001/JAMA.2011.1332
P407
P577
2011-09-01T00:00:00Z